T hroughout phylogeny, positive transcriptional control plays a important role in cellular decision-making (45). The mechanisms that activate transcription initiation in response to environmental and metabolic signal inputs are varied and involve complex sensory functions linked to specific macromolecular interactions conducted at targeted chromosomal loci. For many regulatory systems, these interactions involve contacts between transcriptional regulators and RNA polymerase (RNAP). In prokaryotes, RNA polymerase, composed of ␤, ␤=, , 2 ␣, and subunits, contains multiple target surfaces that can engage positive regulatory proteins, which function to direct RNAP to the specific regulatory regions of genes that are under their control (17). The ␣ subunit, bearing two domains that occupy the protein's N and C termini (NTD and CTD, respectively), is a common target for regulatory protein interaction (18). A classic example is the class I and II positive control exerted by the cyclic AMP (cAMP) receptor protein-cAMP complex (CRP-cAMP), which interacts with a specific cis-acting element upstream of promoter DNA as a dimeric complex that recruits RNAP by direct interaction with RNAP ␣CTD (4).
T hroughout phylogeny, positive transcriptional control plays a important role in cellular decision-making (45) . The mechanisms that activate transcription initiation in response to environmental and metabolic signal inputs are varied and involve complex sensory functions linked to specific macromolecular interactions conducted at targeted chromosomal loci. For many regulatory systems, these interactions involve contacts between transcriptional regulators and RNA polymerase (RNAP). In prokaryotes, RNA polymerase, composed of ␤, ␤=, , 2 ␣, and subunits, contains multiple target surfaces that can engage positive regulatory proteins, which function to direct RNAP to the specific regulatory regions of genes that are under their control (17) . The ␣ subunit, bearing two domains that occupy the protein's N and C termini (NTD and CTD, respectively), is a common target for regulatory protein interaction (18) . A classic example is the class I and II positive control exerted by the cyclic AMP (cAMP) receptor protein-cAMP complex (CRP-cAMP), which interacts with a specific cis-acting element upstream of promoter DNA as a dimeric complex that recruits RNAP by direct interaction with RNAP ␣CTD (4) .
While direct interaction between DNA-bound regulators and RNAP is a common mechanism of positive transcriptional control, mechanisms of RNAP appropriation and "prerecruitment" have been reported that involve initial RNAP-regulator interaction prior to promoter engagement (2) . Proteins encoded in bacteriophage genomes, such as NS4SSB of phage N4 (26) and AsiA of phage T4 (15) , target RNAP without contacting DNA and yet participate in gene-specific transcriptional activation. The SoxS protein that mediates the bacterial response to superoxide, and the MarA protein that functions in control of multidrug resistance mechanisms, first contacts the RNAP ␣ subunit prior to sequencespecific DNA interaction (11, 25) . Spx, a protein of low-GC-content Gram-positive bacteria that serves as a transcriptional activator of genes that function in thiol-specific oxidative stress (11, 25, 51) , also exerts control of RNAP through a prerecruitment mechanism (31) .
Spx governs a large regulon of genes that includes those encoding thioredoxin (trxA), thioredoxin reductase (trxB) (34) , and methionine sulfoxide reductase (49) and genes whose products function in bacillithiol biosynthesis (9) , cysteine biosynthesis (35) , and iron uptake and metabolism (52) . Spx has also been linked to control of biofilm-and virulence-related functions (19, 39) . Spx is under multiple levels of control that operate at the transcriptional and posttranscriptional level. Multiple forms of RNAP target the operon in which the spx gene resides (8, 41) . The spx gene itself is under negative transcriptional control involving two repressors, YodB and PerR, that control the transcriptional response to toxic electrophiles and peroxide, respectively (23) . Spx protein is under tight proteolytic control involving the ATP-dependent protease ClpXP (35, 36) and a cognate proteolysis-enhancing factor, YjbH (10, 21) . Encounters with any one of a variety of toxic agents can result in an elevated Spx concentration and Spx activation (1, 5, 8, 38, 46, 49) .
Spx protein bears a CXXC disulfide redox center that controls its transcription-stimulating activity (34) . Spx in its oxidized, disulfide form productively interacts with RNAP, forming a complex that contacts promoters bearing a cis-acting element (having the sequence a/tGCA followed by an AT-rich sequence) located immediately upstream of the promoter Ϫ35 region (31, 44) . While Spx cannot by itself interact with DNA, a complex consisting of Spx and ␣CTD interacts with DNA that bears the cis-acting element of the Spx-controlled promoter (31) . From mutational analysis of promoter DNA and studies of Spx/␣CTD-DNA interactions, evidence was obtained suggesting that two Spx/␣CTD complexes might participate in Spx-controlled promoter recognition (31) . The notion of two Spx proteins, each binding an ␣ subunit, engaging RNAP has significant implications when considering the roles of multiple Spx paralogs that are encoded within the genomes of several low-GC-content Gram-positive species (19, 43, 47) , including pathogenic streptococci. Could two paralogous forms of Spx engage RNAP, thus expanding the promoter recognition and sensory capabilities of the Spx/RNAP complex?
In the study reported here, the composition of the Spx/RNAP complex was examined using differentially affinity-tagged Spx proteins. Results of affinity interaction chromatography experiments performed with in vitro-assembled complexes of epitopetagged Spx and RNAP, as well as complexes collected from extracts of cells expressing tagged Spx derivatives, indicate that the Spx/RNAP complex bears a single Spx monomer.
MATERIALS AND METHODS
Bacterial strains and culture conditions. All bacterial strains and plasmids are listed in Table S1 in the supplemental material. The Bacillus subtilis strains used in this study are derivatives of JH642 and were grown at 37°C in 2ϫ yeast extract-tryptone (2ϫYT) or Difco sporulation medium (DSM) (14) . Escherichia coli DH5␣ was used for plasmid construction and was grown at 37°C in 2ϫYT liquid or on Luria-Bertani (LB) solid medium containing 1.2% agar (Difco). For overproduction and purification of Spx proteins in E. coli, ER2566 strains (New England Biolabs) bearing spx-overexpressing plasmids were grown at 37°C in LB liquid medium. Antibiotic concentrations used were as previously reported (6) .
Construction of epitope-tagged Spx derivatives. To construct the expression plasmids producing epitope hemagglutinin (HA)-or c-Myctagged Spx proteins, DNA fragments encoding HA and c-Myc tags were generated by annealing the forward and reverse oligonucleotides whose sequences correspond to HA or c-Myc codons (oAL29/oAL30 for c-Myc tag; oAL33/oAL34 for HA tag [oligonucleotide sequences are listed in Table S2 in the supplemental material]), followed by PCR. The fragments generated were cleaved with BamHI and SalI and inserted into pUC18 that was cleaved with BamHI and SalI to create pAL39 and pAL40 carrying a cMyc and an HA tag, respectively. In order to distinguish Spx variants by molecular weight (MW), a truncated spx lacking codons specifying the carboxyl-terminal 12 amino acids (spx⌬C) was generated by PCR using oligonucleotides oMMN01-135 and oAL35. PCR-amplified full-length and truncated spx fragments were then cloned into pAL39 and pAL40 to create pAL47 and pAL42 containing spxc-Myc and spx⌬CHA, respectively. These constructs served as PCR templates for the following constructions.
To evaluate the activity of epitope-tagged Spx variants in B. subtilis, the alleles specifying the variants were integrated into the amyE locus by the use of the pDR111 integration vector (3) and expressed from an IPTG (isopropyl-␤-D-thiogalactopyranoside)-inducible Pspankhy promoter. The construction of pDR111 derivatives was described in a previous study (35) . Briefly, the spx fragments were amplified from plasmids carrying spxc-Myc or spx⌬CHA with upstream oligonucleotide oMMN01-173 and downstream oAL32 or oAL36 specifying the cMyc or HA tag, respectively. DNA fragments were digested with HindIII and SalI and cloned into pDR111 that was digested with the same enzymes. The recombinant plasmids were introduced by transformation into B. subtilis strains carrying a trxB-lacZ fusion at the thrC locus (44) . For the HA-tagged Spx mutants, two-step PCR-based mutagenesis was performed to generate the desired amino acid substitution as detailed in a previous study (31) . The previously constructed pSN56 bearing C-terminal amino acid substitutions (AN to DD) of Spx, which renders Spx resistant to ClpXP proteolysis (35) , was used as a positive control. To express epitope-tagged Spx protein in E. coli for protein purification, the epitope-tagged spx fragments were amplified from pAL47 or pAL42 with forward oligonucleotide oMMN01-135 and reverse oAL31 or oAL35 for the cMyc or HA tag, respectively. DNA fragments were digested with NcoI and SmaI and then cloned into pTYB4, which is an E. coli expression vector used in the Impact kit (New England Biolabs). The recombinant plasmids were introduced by transformation into E. coli strain ER2566.
To investigate Spx and RNAP interaction in vivo, two forms of ClpXP-resistant Spx with distinguishable molecular weights were produced in B. subtilis. To replace the native spx gene with spx⌬C by double crossover, spx with upstream and downstream flanking regions was PCR amplified with oligonucleotides oML02-07/oMMN07-357 and oAL43/oAL44, respectively, and the resultant PCR products were cloned into pUC19 to create pAL78 and pAL79. For antibiotic selection, a kanamycin-resistant (Km r ) cassette isolated from pDG783 (12, 13) was inserted immediately downstream of the spx sequence in pAL78 to create pAL80. To create a clone containing spx::Km for integration into the spx locus, a downstream sequence was cut from pAL79 with BamHI and EcoRI and inserted into pAL80 to create pAL81, which was used for B. subtilis transformation. For ectopic, IPTG-inducible spx⌬CHA expression from the amyE locus, pAL45 (mentioned above) was used to transform B. subtilis.
␤-Galactosidase assays. Strains bearing a trxB-lacZ fusion were grown at 37°C overnight on DSM agar plates supplemented with appropriate antibiotics. The overnight cultures were used to inoculate the same liquid medium at a starting optical density at 600 nm (OD 600 ) of 0.02. When the OD 600 of the cultures reached 0.4, the cultures were divided into two flasks and 1 mM IPTG was added to one of the flasks. Samples were collected every 30 min, and ␤-galactosidase activity was assayed as previously described (30) ; data are presented as Miller units (27) .
Protein purification. His-tagged, A -depleted RNAP (SAd-RNAP) was purified from A mutant B. subtilis strain ORB5853 [rpoC-His 10 sigA(L366A)], in which the Leu366 substitution in A weakens the interaction with the RNAP core enzyme (52) . B. subtilis cells were grown in 2ϫYT liquid containing chloramphenicol and neomycin at 37°C until the OD 600 of the culture reached 0.8 to 0.9 and were then harvested by centrifugation at 2,000 ϫ g. The pellets were frozen at Ϫ80°C prior to purification. Nickel-nitrilotriacetic acid (Ni-NTA; PerfectPro) (5=) affinity column, heparin column, and Bio-Rad High Q column chromatography was performed as previously described (31, 44) . (Note that Spx was previously reported to interact with Ni-NTA resin [32] , but the resin used in this study did not bind native Spx protein.) RNAP was purified and stored at Ϫ20°C in buffer containing 10 mM Tris-HCl (pH 7.8), 100 mM KCl, 5 mM MgCl 2 , 0.1 mM EDTA, and 50% glycerol.
The genes specifying A and Spx variants were cloned in plasmid pTYB4 (Terminus Impact-CN system; New England Biolabs). The products of the recombinant plasmids bear a self-cleavable intein domain and a chitin-binding domain positioned at the C termini.
A was overproduced from plasmid pSN64 (28) in E. coli ER2566 and purified by using chitin resins (New England Biolabs) followed by a Bio-Rad High Q column. Purified protein was dialyzed and stored at Ϫ80°C in buffer containing 25 mM Tris-HCl (pH 8.0), 100 mM KCl, 0.1 mM EDTA, 1 mM MgCl 2, and 10% glycerol. Spx variants were expressed from the pTYB4 derivatives listed in Table S1 in the supplemental material. As previously described, Spx proteins were purified by using a chitin column followed by a Bio-Rad High S column (29) . For the affinity interaction assay, all of the Spx proteins were concentrated to 10 M and stored at Ϫ80°C in buffer containing 10 mM Tris-HCl (pH 8.0), 100 mM KCl, and 5% glycerol.
In vitro transcription.
A linear trxB promoter DNA template was generated by PCR with oligonucleotides oDYR07-32 and oDYR07-52 (30) to yield a fragment that would direct the synthesis of a 66-nucleotide (nt) transcript. For the reaction, the template (10 nM) and RNAP (25 nM), together with 25 nM A , were incubated without or with 75 nM Spx protein in 17.8 l of 10 mM Tris-HCl (pH 8.0), 50 mM NaCl, 5 mM MgCl 2 , and bovine serum albumin (BSA; 50 mg/ml). After a 10-min incubation at 37°C, 2.2 l of a nucleotide mixture (200 mM ATP, GTP, and CTP, 10 mM UTP, 5 mCi [␣-
32 P]UTP) was added. After incubation at 37°C for 8 min, 10 l of stop solution (1 M ammonium acetate, 0.1 mg of yeast RNA, and 0.03 M EDTA) was added to the reaction. The mixture was precipitated with ethanol, and the pellet was dissolved with 5 ml of formamide dye (0.3% xylene cyanol, 0.3% bromophenol blue, and 12 mM EDTA dissolved in formamide). The samples were heated at 90°C for 2 min and were applied to an 8% polyacrylamide-urea gel. The dried gels were scanned on a Typhoon Trioϩ variable imager (GE Healthcare).
To confirm that pulldown complexes were active, the RNAP/Spx complex-bound anti-HA resin was directly used in transcription reactions. An in vitro anti-HA affinity interaction assay was performed on a reaction mixture containing 0.25 M SAd-RNAP, 0.25 M A , and 2.5 M Spx⌬CHA. After washing, instead of elution of the protein with triethylamine, resin was suspended in 40 l of reaction buffer (RB; 10 mM TrisHCl [pH 8.0], 50 mM NaCl, 5 mM MgCl 2 ). A 10-l volume of resin suspension was directly added in the transcription reaction buffer with 10 nM trxB (Ϫ115 to approximately ϩ47) promoter DNA, and the reaction was performed as outlined above.
For the in vitro transcription with RNAP/Spx/DNA complex-bound resins, an in vitro anti-HA affinity interaction assay was performed with a reaction mixture containing 0.25 M SAd-RNAP, 0.25 M A , 2.5 M Spx⌬CHA, and 0.2 M trxB (Ϫ50 to approximately ϩ20) promoter DNA in the presence of 1 mM rATP. A 10-l volume of resin suspension, or 1 l of input or flowthrough from the column, was added to separate reaction tubes and the in vitro transcription was performed as described above.
In vitro affinity interaction assay. To detect proteins interacting with HA-tagged Spx in vitro, 40 l of the anti-HA affinity matrix was preequilibrated with 10 column volumes (CV) of RB and blocked with 4 CV of blocking buffer (5% skim milk in RB) followed by washing with 8 CV of RB. For the reaction, 0.25 M His-tagged SAd-RNAP and 2.5 M Spx⌬CHA were incubated with or without 0.25 M A in 150 l of RB at room temperature. After 20 min, the protein mixture was then applied to the anti-HA affinity column followed by washing with 10 CV of washing buffer (0.05% Tween 20 in RB) and with 10 CV of RB. The protein complex was eluted from the column with 80 l of 100 mM triethylamine (pH 11.5) and neutralized with a 1/10 volume of 1 M Tris-HCl (pH 6.8). The composition of the protein complex was analyzed on the 15% sodium dodecyl sulfate (SDS)-polyacrylamide gel followed by Coomassie blue G250 staining.
For the competition experiments, 2.5 or 7.5 M Spxc-Myc was incubated together with RNAP and Spx⌬CHA in RB. To confirm the stoichiometry of Spx in the complex, the 2-column pulldown assay was also performed. After the protein mixture was prepared, instead of being directly applied to anti-HA column, it was applied to a 40-l Ni-NTA column, followed by washing with 20 CV of RB containing 30 mM imidazole. Complexes were eluted with 80 l of RB containing 200 mM imidazole. The elution from the Ni column was next applied to a 40-l anti-HA column, and the same procedure as described above was followed.
For the interaction assay reaction carried out in the presence of promoter DNA, a trxB promoter fragment from position Ϫ50 to position ϩ22 was PCR amplified with oligonucleotides oKE-9 and oDYR06-3 and purified from a low-melting agarose gel. In the reaction mixture containing 0.25 M SAd-RNAP, 2.5 M Spx⌬CHA, and 2.5 M Spxc-Myc, with or without 0.25 M A , 0.2 M trxB DNA was added in the presence of 20 M initiating rATP in RB. The protein mixture was incubated at 37°C for 30 min and applied to a 40-l anti-HA column. The same affinity pulldown procedure as detailed above was then conducted.
In vivo affinity interaction assay. To investigate the RNAP-Spx complex generated in vivo, a B. subtilis strain, ORB8130, which produces a His-tagged RNAP and bears the spx⌬C allele in the spx locus and an IPTG-inducible spx⌬CHA allele in the amyE locus, was generated. Briefly, the B. subtilis JH642 strain was first transformed with pAL45 with selection for spectinomycin resistance to create strain ORB8121. To express His-tagged rpoC in B. subtilis, ORB8121 was transformed with chromosomal DNA of strain MH3656 (40) with selection for chloramphenicol resistance to create ORB8129. Because overexpression of Spx affects competence, the last step involved replacing the spx gene with the spx⌬C allele by transforming ORB8129 with pAL81 with selection for neomycin resistance. The resultant ORB8030 strain was grown at 37°C overnight on an LB agar plate supplemented with chloramphenicol, neomycin, and spectinomycin. The overnight cultures were used to inoculate 1 liter of the DSM liquid medium supplemented only with chloramphenicol and spectinomycin. When the OD 600 of the cultures reached 0.4, 0.5 mM IPTG was added. After 30 min of incubation at 37°C, when the OD 600 reached 0.8, cells were harvested by centrifugation at 2,000 ϫ g, and the pellets were frozen at Ϫ80°C. A cell pellet was suspended in 10 ml of RB containing 1 protease inhibitor cocktail tablet (Complete Mini [EDTA-free]; Roche) and lysed by passage twice through a French press. The crude lysate was then centrifuged at 26,800 ϫ g and 4°C for 30 min, and the supernatant was filtered through a 0.22-m-pore-size MILLEX-GP filter (Millipore). For affinity interaction assays with anti-HA resins, 500 l of the clear lysate (10 mg/ml) was applied to a 40-l anti-HA affinity column, and the same procedure as described above for the in vitro pulldown reaction was conducted. The flowthrough, wash, and elution fractions were analyzed using SDS-polyacrylamide gel electrophoresis (PAGE) and by Western blotting using anti-Spx or anti-His antiserum.
For two-column pulldown assays, the cleared lysate (around 9.5 ml) was applied to a 1-ml Ni-NTA column and incubated at 4°C for 1 h. The Ni column was washed with 20 CV of RB containing 30 mM imidazole, and the protein complex was eluted with 2 ml of RB containing 200 mM imidazole. The elution fraction from the Ni column was applied to a 0.5-ml anti-HA column. The anti-HA resin was washed with 10 CV of washing buffer and 10 CV of RB as described above. The protein complex was eluted with 2 ml of 100 mM triethylamine (pH 11.5) and neutralized with 1 M Tris-HCl (pH 6.8), followed by concentration with a 3-kDa Amicon ultracentrifugal filter (Millipore) to an appropriate volume for loading onto the SDS-polyacrylamide gel (less than 30 l per lane). The composition of protein complex was analyzed using an SDS-polyacrylamide gel and by Western blotting using anti-Spx or anti-His serum.
Gel filtration chromatography. To determine whether Spx proteins form homodimers in solution, gel filtration chromatography was performed. Purified Spx or Spx⌬CHA was applied to the column packed with Bio-Gel P-60 polyacrylamide gel (Bio-Rad) and run with buffer containing 10 mM Tris-HCl (pH 8.0), 100 mM KCl, and 2% glycerol. The void volume and the calibration curve were determined by using a gel filtration LMW calibration kit (GE Healthcare) and plotting a standard K av -logMW graph. The partition coefficient, K av , of each protein was calculated by using the equation K av ϭ (Ve Ϫ Vo)/(Vc Ϫ Vo), where Vo ϭ void volume, Ve ϭ elution volume, and Vc ϭ geometric column volume. By correlating the K av value of Spx protein to the calibration curve, the composition of Spx protein in the solution was determined.
RESULTS

Epitope-tagged versions of Spx are active in vivo and in vitro.
Allelic variants of spx were constructed that specified modifications to the C-terminal ends of each product. Oligonucleotide PCR primers specifying the HA and c-Myc epitopes were used to create alleles encoding C-terminal epitope-tagged ver-sions of Spx and a deletion variant missing the 12 C-terminal amino acid residues. Previous studies had shown that the deletion of the 12 C-terminal residues created an active, proteaseresistant version of Spx (Spx⌬C [see below]; C. M. Chan and P. Zuber, unpublished data). The epitope-tagged variants included HA-tagged Spx⌬C (Spx⌬CHA), as well as c-Myctagged, full-length Spx protein (Spxc-Myc) (see Fig. S1A in the supplemental material). Spx⌬CHA and Spxc-Myc were tested in vivo by ectopic expression from an IPTG-inducible promoter in the amyE locus within a strain bearing the trxB-lacZ fusion (Fig. 1A and B) , expression of which is stimulated by Spx (44) . A construct bearing an allele of spx encoding the proteaseresistant form of Spx (Spx DD [35] ) was used in parallel as a positive control. Both of the epitope-tagged variants showed activity in vivo, based on the level of trxB-lacZ expression after IPTG addition, but activity was lower by around 50% compared to the Spx DD control level. This reduction in activity was not due to a defect in Spx protein in terms of its ability to activate trxB expression but was due to residual proteolytic control that reduced the HA-and c-Myc-tagged Spx concentration. The activity of the epitope-tagged derivatives was examined in a yjbH null mutant background (Fig. 1A and B) , which showed that the activity of the two epitope-tagged Spx variants was the same as that of Spx DD . This indicated that the reduced activity of the two epitope-tagged Spx variants was due to the sensitivity of the proteins to YjbH-mediated proteolysis catalyzed by ClpXP. To confirm that the Spx⌬CHA and Spxc-Myc proteins were active, the proteins were produced as intein-chitin binding domain fusions and purified by chitin column affinity chromatography and intein cleavage (see Fig. S1A in the supplemental material). After further purification by anion-exchange chromatography, each protein was applied to a transcription reaction mixture containing trxB promoter DNA and purified RNAP holoenzyme (see Fig. S1B in the supplemental material) . Both epitope-tagged versions of Spx stimulated trxB transcription in vitro, using the same transcriptional start site as the wild-type Spx/RNAP complex.
Spx⌬CHA and Spxc-Myc interaction with RNAP confirmed by affinity chromatography. To examine the composition of Spx/RNAP, affinity chromatography designed to capture Spx bound to RNAP was undertaken. RNAP and Spx⌬CHA were combined in a 1:10 molar ratio in a binding reaction that was applied to an anti-HA affinity column that had been blocked with buffer containing milk to prevent nonspecific protein binding. Elution of Spx⌬CHA with associated RNAP was accomplished with a high pH buffer and confirmed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) ( Fig. 2A) . RNAP did not interact with the anti-HA column (Fig. 2B) . Spxc-Myc bound to RNAP could also be captured by an anti-c-Myc affinity column, and eluted fractions could be resolved by SDS-PAGE, showing Spxc-Myc and bound RNAP (Fig. 2D) , while RNAP showed weak interaction with the anti-c-Myc column. By the use of the sigA(L366A) B. subtilis mutant (kindly provided by C. P. Moran, Jr., Emory University), a A defect in RNAP core enzyme interaction (52) in a preparation of RNAP depleted of A (SAd-RNAP) was obtained (see Fig. S1A in the supplemental material). As shown in Fig. S1B in the supplemental material, RNAP from the sigA(L366A) mutant did not transcribe the trxB template, but transcripts were detected after purified A protein was applied to the reaction. Further addition of Spx stimulated transcription from the Spx-controlled trxB promoter. Binding of A -depleted RNAP with Spx⌬CHA was observed by anti-HA affinity chromatography, although binding affinity of Spx⌬CHA with RNAP was higher when A was present ( Fig. 2A and C) . Repeat binding reaction mixtures containing SAd-RNAP and Spx⌬CHA were applied to the anti-HA Affi-Gel column. SAd-RNAP coeluted with Spx⌬CHA; however, the amount of bound enzyme was less than that obtained in reactions using holo-RNAP (see Fig. S2A and B in the supplemental material). The result suggested that A is required for optimal Spx-RNAP interaction. Note that RNAP holoenzyme and SAd-RNAP showed no affinity for the anti-HA AffiGel column (see Fig. S3 in the supplemental material) .
To test the interaction of RNAP with Spx mutants that show defects in transcriptional activation, anti-HA Affi-Gel interaction reactions were assembled with proteins having substitutions at residue positions known to be required for Spx activity. An Spx⌬CHA variant bearing a G52R mutation, shown previously to disrupt Spx-␣CTD interactions, was combined with RNAP holoenzyme or SAd-RNAP. After incubation, the mixture was applied to the anti-HA affinity column. Immobilized complexes were eluted at high pH and analyzed by SDS-PAGE (Fig. 3A and B) . The Spx-RNAP interaction was quantified by calculating the ratio of Spx band intensity to large subunit (␤, ␤=) band intensity. The Spx⌬CHAG52R mutant showed significantly reduced affinity for RNAP holoenzyme, and the data were in line with previous results (31, 37) . A similar result was obtained for reaction mixtures containing a mutant form of RNAP holoenzyme bearing an ␣ subunit with a Y263C substitution that does not interact efficiently with Spx (see Fig. S4 in the supplemental material) (33) . These experiments confirmed that spx and rpoA mutations that compromise Spx-␣ interaction disrupt Spx-RNAP complex formation. In contrast, the Spx(R60E) and Spx(C10A) mutants were expected to interact with RNAP. The Spx(R60E)⌬CHA and Spx(C10A)⌬CHA mutant proteins interacted with RNAP holoenzyme with an affinity only slightly less than that of the parent Spx⌬CHA but showed noticeably reduced affinity for SAd-RNAP (Fig. 3C and  D) . Spx(R60E) and Spx(C10A) exert negative transcriptional control in vivo by direct interaction with RNAP but are severely defective in transcriptional activation, which is the result of poor binding to their DNA target when complexed with ␣CTD (31, 34, 50) .
Spx⌬CHA and Spxc-Myc compete for RNAP interaction. One view of the composition of Spx/RNAP is that two Spx proteins, one bound to each ␣ subunit, would associate with RNAP and generate a transcription activation complex in which two cis-acting Spx response elements would be utilized to stimulate transcription from an Spx-controlled promoter (31) . Experiments were conducted with epitope-tagged Spx variants to determine if Spx/RNAP contains two Spx monomers. A reaction was assembled in which Spx⌬CHA and SpxcMyc were combined with holo-RNAP and then applied to the anti-HA affinity column. As shown in Fig. S1 in the supplemental material, the two Spx variants can be distinguished by SDS-PAGE according to the differences in their molecular weights. Elution of the complex from the anti-HA column should have resulted in coelution of RNAP and Spxc-Myc protein if the transcription complex contained two Spx monomers. The gel profile of the eluted fraction showed that only the HA-tagged Spx variant and associated holo-RNAP (Fig. 4A and B) or SAd-RNAP ( Fig. 4C and D) bound to the anti-HA column, while Spxc-Myc was found in the flowthrough and wash fractions. The elution was carried out at high pH, and the fraction collected was not active in an in vitro transcription reaction. However, the immobilized complex on the anti-HA Affi-Gel beads was active in transcription reactions when combined with trxB promoter DNA and radiolabeled nucleotide mixture (see Fig.  S5 in the supplemental material). The results indicate that the active Spx/RNAP complex is composed of a single Spx protein.
The same result was obtained when the reaction was applied to an anti-c-Myc Affi-Gel (see Fig. S6 in the supplemental material). Following elution and gel electrophoresis, Spxc-Myc was found to be associated with RNAP, and a protein of lower molecular weight was barely detectable beneath the Spxc-Myc band, which might have reflected a small amount of RNAP nonspecifically bound to the column (see Fig. S6 in the supplemental material) or a degradation product of Spxc-Myc, which we observed in some of the SDS-PAGE and Western blot analyses.
The experiment was repeated by first purifying RNAP in the presence of Spx⌬CHA and Spxc-Myc protein by the use of an Ni-NTA column, taking advantage of the rpoC allele encoding a His-tagged ␤= subunit (40) . Figure 5 shows the input of RNAP (I R ) followed by Spx⌬CHA and Spxc-Myc input (I S ). Elution with imidazole recovers RNAP bound to the Spx proteins. This was then applied to the Affi-Gel anti-HA column, and the eluted fraction again contained only Spx⌬CHA and RNAP, while Spxc-Myc was found in the flowthrough fraction.
The possibility that promoter DNA was required for the interaction of two Spx monomers with the Spx-activated transcription complex was tested using the two epitope-tagged forms of Spx. A segment of trxB promoter DNA used in previous electrophoretic mobility shift assay (EMSA) studies containing a sequence from Ϫ50 to ϩ20 (31) was added to the binding reaction mixture containing Spx⌬CHA, Spxc-Myc, and RNAP. The reaction mixture was applied to the anti-HA column, and fractions collected from the column were analyzed by SDS-PAGE and Western blotting using anti-Spx antiserum. The addition of trxB promoter DNA had no effect on the Spx interaction with RNAP. Again, only the Spx⌬CHA protein was found in the elution with RNAP, and no Spxc-Myc protein was detected (Fig. 6A) . In vitro transcription using the flowthrough and beads showed that the Spxc-Myc/RNAP and Spx⌬CHA/RNAP complexes were transcriptionally active (Fig.  6B) , yielding the expected 20-nucleotide transcript.
The finding that only one Spx protein establishes contact with RNAP suggests that other forms of Spx, such as the reported paralogous forms in certain Gram-positive bacteria, could potentially compete for RNAP. The Spx-RNAP pulldown experiment using Spx⌬CHA and Spxc-Myc proteins was repeated with a 3-fold-higher concentration of Spxc-Myc. As predicted, when excess Spxc-Myc was present in the binding reaction that was applied to the anti-HA Affi-Gel column, less RNAP coeluted with Spx⌬CHA ( Fig. 4A and B) . To rule out the possibility that the extended C terminus of the Spxc-Myc protein inhibited interaction of a second Spx monomer with Spx/RNAP, wild-type Spx protein was added to the binding reaction mixture containing Spx⌬CHA and RNAP. The two Spx proteins are nearly the same molecular weight and cannot be distinguished by SDS-PAGE. However, the same reduction in Spx⌬CHA-RNAP interaction was observed when a 3-fold excess of Spx was added to the binding reactions (data not shown). Competition for SAd-RNAP was also observed when Spxc-Myc was added in excess to the binding reaction mixture containing Spx⌬CHA and SAd-RNAP (Fig. 4C  and D) .
Evidence that Spx is a monomer in solution. A possible explanation for why two differentially tagged versions of Spx do not engage RNAP simultaneously might be that Spx forms a dimer in solution and that the dimer of Spx⌬CHA is in contact with the two ␣ subunits of Spx. Previous reports argue against this possibility. The crystal structure of an in vivo-assembled Spx/␣CTD complex shows no interaction between Spx monomers (20) , and no Spx in dimeric form was generated in an Spx/␣CTD complex assembled in vitro (37) . Second, ArsC, the structural homolog of Spx, functions as a monomer (24) . We performed a glutaraldehyde crosslinking experiment (see Fig. S7 in the supplemental material), using Spx ␣CTD and ␣ protein alone as positive controls, indicating that the majority of Spx⌬CHA and wild-type Spx protein in solution is monomeric whereas cross-linked versions of Spx/ ␣CTD and ␣/␣ complexes can be detected. Notably, the Spx/ ␣CTD cross-linked product is the size that would be predicted if one monomer of Spx interacted with ␣CTD. Size exclusion chromatography with molecular weight markers showed that Spx⌬CHA elutes from the column between MW 13 and 29, indicating a monomeric form of the protein (see Fig. S7B in the supplemental material). 
FIG 5
In vitro two-column interaction assay of Spx/RNAP complex. His-tagged RNAP holo or SAd-RNAP was immobilized on an Ni-NTA column, and a mixture of Spx⌬CHA and Spxc-Myc at a 1:1 molar ratio was applied to the RNAP prebound Ni column. The Spx/RNAP complex was eluted with buffer containing 200 mM imidazole, and the elution fraction was directly applied to an anti-HA affinity column. The Spx/RNAP complex was captured through the Spx⌬CHA interaction and eluted at high pH. All the fractions from the two columns were collected and analyzed by SDS-PAGE and Western blotting using Spx antibodies. Abbreviations: I R , RNAP input; FT 1 , RNAP flowthrough; I s , Spx input; FT 2 , Spx flowthrough; W, wash; E/I c , elution from Ni column and input for anti-HA column; FT, complex flowthrough; E, elution.
Wild-type Spx does not confer activity to an Spx(R60E)⌬CHA/ RNAP complex. Evidence from affinity interaction experiments indicates that a single Spx protein interacts with RNAP to form the transcription activation complex, although it was possible that a small, undetectable amount of RNAP bound to two Spx proteins was captured on the anti-HA column. The possibility that two Spx proteins are capable of binding RNAP but that only one is active was tested by the following experiment. A binding reaction was assembled that contained Spxc-Myc, RNAP, and Spx(R60E)⌬CHA and was applied to the anti-HA Affi-Gel column. Affi-Gel beads were retrieved to determine the transcriptional activity of the complex. As was observed in the previous experiments, only the HA-tagged form of Spx was detected in the elution fraction, as determined by SDS-PAGE and Western blot analyses (Fig. 7A) . The anti-HA beads containing immobilized Spx(R60E)⌬CHA-RNAP complex had no activity when trxB promoter DNA was added to immobilized mutant Spx/RNAP complexes on anti-HA resin in the presence of NTPs and radiolabeled UTP (Fig. 7B) . No transcriptional activity was detected in the resin-bound Spx/ RNAP complex when trxB promoter DNA was added to the binding reaction with RNAP, Spxc-Myc, and Spx(R60E)⌬CHA prior to column chromatography (Fig. 7C) . These results indicate that active Spx does not productively associate with an RNAP complex bearing an inactive Spx variant.
A single Spx monomer interacts with RNAP in vivo. The data of Fig. 2 to 6 were generated in experiments using purified Spx and RNAP to assemble complexes in vitro. To gain an understanding of Spx/RNAP complex composition in vivo, an experiment was conducted to recover RNAP from cells in which Spx variants with differentially modified C termini were produced. Two spx alleles were expressed; one resided in the spx locus and encoded Spx⌬C, which is active but missing the C-terminal 12 amino acids, while at the amyE locus, a version of spx encoding Spx⌬CHA was expressed from an IPTG-inducible promoter. Spx⌬CHA could be distinguished from the Spx⌬C protein on SDS-PAGE by its higher molecular weight. The strain bearing the two spx alleles also contained an allele of rpoC (␤=) whose product has a C-terminal His tag designed for RNAP purification (39) .
Cells of the spx diploid strain were grown in DSM to an OD 600 of 0.4 and then treated with IPTG. Cells were harvested after 30 min and lysed by French press. The lysate was applied to an anti-HA column, which was washed and finally treated with high-pH elution buffer. Western analysis of the column fractions showed that only the Spx⌬CHA protein was eluted from the column (Fig. 8A) , while the ⌬C product was found in the flowthrough fraction. This result supported previous structural data and the experimental data in Fig. S7 in the supplemental material, indicating that Spx does not form a homomultimer (30) . Western analysis of the fractions using an anti-His tag showed that RNAP copurified with Spx⌬CHA in the affinity interaction assay reaction.
A sample of lysate, prepared in the same manner as described above, was applied to an Ni-chelate chromatography column. SDS-PAGE of the eluted RNAP showed that the two Spx products coeluted (Fig. 8B, showing replicate results) , indicating that both are capable of interacting with RNAP in vivo. The eluted fraction was then applied to the anti-HA Affi-Gel column, which was washed and then treated with high-pH elution buffer. The fractions were applied to two SDS-PAGE gels, and the resolved proteins were blotted onto nylon filters for Western analysis using anti-Spx and anti-His tag antibody. The RNAP and Spx⌬HA were detected in the eluted fraction of the Affi-Gel anti-HA column. Spx⌬C, which coeluted with RNAP from the Ni-chelate column, was observed in the flowthrough fraction but was not detectable in the eluted fraction. The results show that both in vivo-produced Spx derivatives were able to interact with RNA polymerase but that only one Spx protein was observed within an Spx/RNAP complex.
DISCUSSION
Previous studies have shown that Spx contacts RNAP ␣CTD to form a complex that can interact with a cis-acting element of Spxcontrolled promoters (31, 37) . The report of these studies posed a hypothesis that two Spx monomers could contact RNAP, forming a complex that could recognize promoters bearing either one or two Spx-responsive sequence elements. Such Spx-responsive elements have been found in the trxA, trxB, nfrA, and ytpQ genes, all of which are transcriptionally activated by Spx. The sequence resides immediately upstream of the Ϫ35 region of the core promoter in all four promoters, while in the trxB and trxA genes, a second element was thought to be located in a sequence overlapping with the Ϫ35 element (31) . Several scenarios could be envisioned to explain the mechanism of Spx/RNAP-promoter interaction. Two Spx monomers, each occupying a binding surface on the RNAP ␣ subunit, might be required for optimal activation, or two Spx monomers bind to RNAP but only one functions in stimulating transcription. A third possibility is that a single Spx monomer engages RNAP and generates the DNA-binding Spx/␣CTD complex for promoter recognition. The evidence reported here strongly supports the third scenario: a single Spx monomer interacts with RNAP holoenzyme to form the active Spx-stimulated transcription complex.
In this third scenario, one of the two ␣ subunits, ␣I bound to ␤ or ␣II to ␤=, is the target of Spx interaction, and binding to either one could result in formation of a transcriptionally active complex. Alternatively, Spx must bind to only one of the two ␣ subunits to productively engage RNAP. In this case, interaction between Spx and RNAP might involve multiple contacts, not only with ␣I or ␣II, but with another subunit, as binding to one or the other would position Spx to contact another specific interaction surface on one of the RNAP subunits. In the Affi-Gel experiments, more RNAP coeluted with Spx when holoenzyme was present in the binding reactions than when SAd-RNAP was applied to the reaction, suggesting that A enhances Spx-RNAP interaction and that the subunit might contribute an interaction surface. However, the exact basis of this effect remains to be investigated.
An excess of Spx protein was applied to each RNAP binding reaction, and yet a significant amount of RNAP remained unbound to Spx. This might have been due, in part, to the aforementioned preference of Spx for A -bearing RNAP holoenzyme but could also have been due to the blocking conditions used to prevent nonspecific binding of protein to the Affi-Gel column. Adding A in 5ϫ molar excess did not significantly increase the proportion of RNAP that could bind Spx. Recently reported proteomic analysis provided evidence that approximately 60% of holoenzyme RNAP is bound to A (7) . While the RNAP preparation used in our studies appeared to be quite pure after a 3-column purification, we cannot rule out the presence of RNAP-associated proteins, such as alternative sigma subunits, that might weaken Spx-RNAP interaction. At present, we do not know if Spx can engage alternative holoenzyme forms or if Spx can associate with elongating RNAP.
CRP-cAMP is capable of interacting with either ␣ subunit as part of its mechanism for stimulating transcription initiation (4). In class I transcriptional activation, the target promoter bears a catabolite activator protein (CAP) site centered at position Ϫ61 and is followed by an AT-rich sequence upstream of the Ϫ35 core promoter element. It is estimated that 3 in 4 class I activated complexes involve contact between a CRP dimer and ␣I subunit (16, 22) . The ␣I CTD that binds CRP interacts with the upstream ATrich region and contacts 70 region 4 positioned at the Ϫ35 promoter sequence. The organization of the class I CRP-activated promoter is similar to that of the promoter sequence targeted by Spx, in that trxB, trxA, ytpQ, and nfrA all contain an upstream AT-rich sequence near the Ϫ35 element (31, 44) . This suggests that productive interaction between a single monomer of Spx and RNAP might require contact between Spx and the CTD of ␣I (Fig.  9 ). That only a single monomer binds RNAP suggests further that ␣ may not be the only binding partner of Spx and that another subunit of RNAP might also serve as an Spx contact site, as suggested above. Further investigation of the Spx-activated transcription initiation complex is required to uncover the RNAP binding surfaces and cis-acting element directly targeted by Spx and the organization of Spx-activated promoters.
The genomes of several low-GC-content Gram-positive bacteria encode multiple paralogs of Spx; B. anthracis has two, SpxA1 and SpxA2, both of which are close homologs of B. subtilis Spx (42) , and Lactococcus lactis has as many as 7 paralogs (48) . With the established target of Spx being the ␣CTD, one could envision that two paralogous Spx forms could engage RNAP and refine the target recognition capabilities of the Spx-RNAP complex. Optimal transcriptional activation would involve interaction of a regulatory region with tandemly arranged sequences specific for each Spx/␣CTD complex. In light of the evidence presented here, which supports a model whereby a single Spx monomer engages RNAP, a more likely possibility is competition among Spx paralogs for RNAP interaction. Thus, synthesis of paralogous forms could be the result of differential expression of individual spx genes, with each product produced under distinct environmental/ metabolic conditions. Each Spx paralog could exert control over its own unique regulon, or paralogous Spx forms might occupy overlapping realms of control, directing the expression of common sets of genes.
